We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MDT Stock Up on Q3 Earnings and Revenue Beat, Margins Down
Read MoreHide Full Article
Key Takeaways
MDT beat Q3 EPS and revenue estimates, with sales up 8.7% and shares rising 2.9% premarket.
MDT's Cardiovascular and Diabetes fueled organic growth, with strong gains in Heart Failure and Acute Care.
Medtronic's gross and operating margins contracted as costs and expenses rose in the quarter.
Medtronic plc (MDT - Free Report) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.36, which fell 2.2% from the year-ago quarter’s figure. The figure beat the Zacks Consensus Estimate by 2.07%.
Without certain one-time adjustments — including amortization of intangible assets, restructuring and acquisition-related costs — GAAP EPS was 89 cents compared with $1.01 in the year-ago period.
MDT’s Q3 Revenues
Worldwide revenues in the reported quarter totaled $9.02 billion, up 8.7% year over year on a reported basis and 6% organically. The top line surpassed the Zacks Consensus Estimate by 1.35%.
Following the announcement today, MDT shares rose 2.9% in premarket trading.
Segmental Analysis of MDT’s Q3 Revenues
The company reports revenues under four major segments — Cardiovascular, Medical Surgical, Neuroscience and Diabetes.
In the fiscal third quarter, Cardiovascular revenues increased 10.6% organically to $3.46 billion.
Within this, Cardiac Rhythm & Heart Failure sales totaled $1.86 billion, up 17% year over year organically. Revenues from Structural Heart & Aortic rose 2.6% organically to $929 million. Coronary & Peripheral Vascular revenues grew 5.9% organically to $672 million.
In the Medical Surgical portfolio, worldwide sales totaled $2.17 billion, up 2.7% year over year organically. While Surgical & Endoscopy revenues edged up 1.4% organically to $1.65 billion, Acute Care & Monitoring revenues jumped 7% to $519 million.
In Neuroscience, worldwide revenues of $2.56 billion were up 2.5% year over year organically. Cranial & Spinal Technologies sales amounted to $1.31 billion, up 3.7% year over year organically. Specialty Therapies revenues totaled $746 million, down 0.2% year over year organically. Neuromodulation revenues grew 3.6% organically to $503 million.
Revenues in the Diabetes group rose 8.3% organically to $796 million.
MDT’s Q3 Margin Performance
The gross margin in the reported quarter contracted 265 basis points (bps) to 63.8% due to a 17.3% rise in the cost of products sold (excluding amortization of intangible assets).
Research and development expenses rose 7% year over year to $722 million. Selling, general and administrative expenses jumped 8.8% to $2.96 billion.
The adjusted operating margin fell 253 bps year over year to 23%.
Medtronic’s Fiscal 2026 Outlook
For fiscal 2026, Medtronic continues to project organic revenue growth of 5.5%. The Zacks Consensus Estimate for fiscal 2026 worldwide revenues is pegged at $36.04 billion.
Full-year adjusted EPS is expected in the range of $5.62-$5.66, which also remains unchanged. The Zacks Consensus Estimate for the year’s adjusted earnings is pegged at $5.64.
Our Take on MDT Stock
Medtronic exited the third quarter of fiscal 2026 with earnings and revenues beating estimates. Performance demonstrated the strength of the portfolio, with organic revenue growth coming ahead of the company’s guidance. Each of the businesses across the Cardiovascular portfolio increased organically. Diabetes, too, gained from performance in the international markets.
During the quarter, Medtronic secured CE Mark for Sphere-360 and FDA clearance for Hugo robotic-assisted surgery. The company also executed its M&A strategy with two key transactions, CathWorks in Coronary and Renal Denervation and Anteris in Structural Heart.
The contraction of both margins is discouraging.
MDT’s Zacks Rank & Key Picks
Medtronic currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Cardinal Health (CAH - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 13.24%.
Cardinal Health,carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter fiscal 2026 adjusted EPS of $2.63, exceeding the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion topped the Zacks Consensus Estimate by 0.9%.
CAH has a long-term earnings growth rate of 15% compared with the industry’s 9.6% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 9.3%.
Align Technology,carrying a Zacks Rank #2 at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
MDT Stock Up on Q3 Earnings and Revenue Beat, Margins Down
Key Takeaways
Medtronic plc (MDT - Free Report) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.36, which fell 2.2% from the year-ago quarter’s figure. The figure beat the Zacks Consensus Estimate by 2.07%.
Without certain one-time adjustments — including amortization of intangible assets, restructuring and acquisition-related costs — GAAP EPS was 89 cents compared with $1.01 in the year-ago period.
MDT’s Q3 Revenues
Worldwide revenues in the reported quarter totaled $9.02 billion, up 8.7% year over year on a reported basis and 6% organically. The top line surpassed the Zacks Consensus Estimate by 1.35%.
Following the announcement today, MDT shares rose 2.9% in premarket trading.
Segmental Analysis of MDT’s Q3 Revenues
The company reports revenues under four major segments — Cardiovascular, Medical Surgical, Neuroscience and Diabetes.
In the fiscal third quarter, Cardiovascular revenues increased 10.6% organically to $3.46 billion.
Medtronic PLC Price, Consensus and EPS Surprise
Medtronic PLC price-consensus-eps-surprise-chart | Medtronic PLC Quote
Within this, Cardiac Rhythm & Heart Failure sales totaled $1.86 billion, up 17% year over year organically. Revenues from Structural Heart & Aortic rose 2.6% organically to $929 million. Coronary & Peripheral Vascular revenues grew 5.9% organically to $672 million.
In the Medical Surgical portfolio, worldwide sales totaled $2.17 billion, up 2.7% year over year organically. While Surgical & Endoscopy revenues edged up 1.4% organically to $1.65 billion, Acute Care & Monitoring revenues jumped 7% to $519 million.
In Neuroscience, worldwide revenues of $2.56 billion were up 2.5% year over year organically. Cranial & Spinal Technologies sales amounted to $1.31 billion, up 3.7% year over year organically. Specialty Therapies revenues totaled $746 million, down 0.2% year over year organically. Neuromodulation revenues grew 3.6% organically to $503 million.
Revenues in the Diabetes group rose 8.3% organically to $796 million.
MDT’s Q3 Margin Performance
The gross margin in the reported quarter contracted 265 basis points (bps) to 63.8% due to a 17.3% rise in the cost of products sold (excluding amortization of intangible assets).
Research and development expenses rose 7% year over year to $722 million. Selling, general and administrative expenses jumped 8.8% to $2.96 billion.
The adjusted operating margin fell 253 bps year over year to 23%.
Medtronic’s Fiscal 2026 Outlook
For fiscal 2026, Medtronic continues to project organic revenue growth of 5.5%. The Zacks Consensus Estimate for fiscal 2026 worldwide revenues is pegged at $36.04 billion.
Full-year adjusted EPS is expected in the range of $5.62-$5.66, which also remains unchanged. The Zacks Consensus Estimate for the year’s adjusted earnings is pegged at $5.64.
Our Take on MDT Stock
Medtronic exited the third quarter of fiscal 2026 with earnings and revenues beating estimates. Performance demonstrated the strength of the portfolio, with organic revenue growth coming ahead of the company’s guidance. Each of the businesses across the Cardiovascular portfolio increased organically. Diabetes, too, gained from performance in the international markets.
During the quarter, Medtronic secured CE Mark for Sphere-360 and FDA clearance for Hugo robotic-assisted surgery. The company also executed its M&A strategy with two key transactions, CathWorks in Coronary and Renal Denervation and Anteris in Structural Heart.
The contraction of both margins is discouraging.
MDT’s Zacks Rank & Key Picks
Medtronic currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Cardinal Health (CAH - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 13.24%.
Cardinal Health,carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter fiscal 2026 adjusted EPS of $2.63, exceeding the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion topped the Zacks Consensus Estimate by 0.9%.
CAH has a long-term earnings growth rate of 15% compared with the industry’s 9.6% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 9.3%.
Align Technology,carrying a Zacks Rank #2 at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.